Standex International Corp saw a small insider sale this week when director Thomas E. Chorman sold 50 shares of company stock on March 2, 2026. The shares traded at $259.00 each, producing a total transaction value of $12,950.00.
The disposal came after the company's shares delivered a 47% gain over the past 12 months, although the price has retreated since the peak and was at $249.41 at the time the related market data was noted. InvestingPro analysis flagged Standex as appearing overvalued at current levels.
Following the sale, Chorman continues to hold a direct position of 12,616 shares of Standex International. The transaction was implemented pursuant to an existing 10b5-1 trading plan that was established on November 6, 2025.
Standex has a market capitalization of $3.02 billion. According to InvestingPro Tips, the company has a 56-year record of consecutive dividend payments; that same InvestingPro resource provides 13 additional insights on the company. For investors seeking more detailed research, a Pro Research Report is available for Standex (SXI) and more than 1,400 other U.S. equities.
In corporate results published for the second quarter of fiscal 2026, Standex topped market expectations on key metrics. The company reported earnings per share of $2.08, above the consensus forecast of $2.00. Revenue was $221.3 million, modestly higher than the $219.22 million that had been anticipated.
Those quarterly results were characterized as being well-received by the market and were described as aligning with analyst projections. The earnings release did not include any reported mergers or acquisitions. Likewise, analyst firms had not issued recent upgrades or downgrades for Standex, leaving the firm in a steady standing with the analyst community.
Taken together, the company's most recent operational performance and the insider transaction provide discrete datapoints for investors assessing Standex's financial condition and market valuation. While the earnings beat and the long dividend streak are cited as indicators of financial health and operational efficiency, InvestingPro's valuation view signals that current market prices may be elevated.
Note on reporting limitations - The available information does not indicate any analyst rating changes or any pending corporate transactions beyond the disclosed quarterly results and the insider sale executed under the 10b5-1 plan.